MedTrace Logo

The Effect of DPP4 Inhibitor on Vasclular Healing

NCT02802644 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2016-06-16

No results posted yet for this study

Summary

This study evaluate the effect of dipeptidyl-peptidase 4 inhibitor on vascular healing after biodegradable polymer based sirolimus eluting stent implantation in diabetic pateints.

Conditions

  • Acute Coronary Syndrome
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Sitagliptin

Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.

DRUG

Non DPP-4 Inhibitor

This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.

Sponsors & Collaborators

  • Chung-Ang University

    lead OTHER

Principal Investigators

  • Sang-Wook Kim, MD, PhD · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02802644 on ClinicalTrials.gov